Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report
Abstract Background Secukinumab has been approved by the U.S. FDA and the European Medicines Agency for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis with the documented adverse effects. Here we reported in one case that a new symptom, Prurigo Nodularis (PN), developed...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-07-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13223-023-00811-5 |